MOPA — Medical Oncology Prior Authorization
0.1.1-snapshot-080926 - snapshot-080926 United States of America flag

MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

PlanDefinition: Example Regimen Definition: PHD (Pertuzumab + Trastuzumab + Docetaxel) (Experimental)

Official URL: http://hl7.org/fhir/us/codex-mopa/PlanDefinition/RegimenPHD Version: 0.1.1-snapshot-080926
Standards status: Informative Computable Name: RegimenPHD

PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.

Metadata
Title PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer
Version 0.1.1-snapshot-080926
Experimental true
Subject Type Malignant neoplasm of breast
Jurisdiction United States of America
Steward (Publisher) HL7 International / Clinical Interoperability Council
Steward Contact HL7 International / Clinical Interoperability Council
Description

PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.
Type Order Set
PlanDefinition Action
Id pertuzumab-phd
Title Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d
Timing Once per 21 days
PlanDefinition Action
Id trastuzumab-phd
Title Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d
Timing Once per 21 days
PlanDefinition Action
Id docetaxel-phd
Title Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle
Timing Once per 21 days
Generated using version 0.5.4 of the sample-content-ig Liquid templates